Back to Results
First PageMeta Content
Vascular-targeting agent / Docetaxel / Angiogenesis / Lung cancer / Prostate cancer / Tyrosine kinase inhibitors / Cyclacel / Nintedanib / Medicine / Chemistry / Organic chemistry


NPI[removed]ADVANCE P2 PR 18Mar09FINAL
Add to Reading List

Document Date: 2011-08-15 11:58:20

Open Document

File Size: 15,77 KB

Share Result on Facebook

City

SAN DIEGO / /

Company

Nereus Pharmaceuticals Inc. / President & CEO Nereus Pharmaceuticals Inc. / /

Continent

South America / /

Country

United States / Australia / India / /

/

Event

FDA Phase / /

Facility

Barbara Ann Karmanos Cancer Institute / /

IndustryTerm

cancer therapies / treatment of cancer / chemical diversity / cancer treatment / /

MedicalCondition

cancers / tumor / cancer / multiple myeloma / tumors / NSCLC / standard cancer / solid tumor / solid tumors / lymphomas / hemorrhagic tumor necrosis / sarcoma / non-small cell lung cancer / infectious diseases / leukemias / inflammation / established tumor / /

MedicalTreatment

oncology therapies / cancer therapies / chemotherapy / /

Organization

Barbara Ann Karmanos Cancer Institute in Detroit / /

Person

Matthew A. Spear / Shirish Gadgeel / /

/

Position

Chief Medical Officer / Assistant Professor / Investor Relations Porter / /

Product

NPI-2358 / /

ProvinceOrState

California / Michigan / /

TVStation

Kobi / /

Technology

pharmacokinetics / drug discovery / polymerization / chemotherapy / /

URL

www.nereuspharm.com / /

SocialTag